Related Experiment Video
Updated: Jul 18, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
First Onset of IgA Vasculitis and Nephritis Following COVID-19 Vaccination
Jesús Iván Martínez-Ortega1, Felipe Perez-Hernandez2, Ilse Fernández-Reyna3
1Department of Dermatology, Dermatological Institute of Jalisco "Dr. José Barba Rubio", Zapopan, MEX.
Abstract:
The article presents a case of a 32-year-old male who developed IgA vasculitis (IgAV) and IgA vasculitis nephritis (IgAVN) after receiving the second dose of the AstraZeneca COVID-19 vaccine. IgAVN can be a rare side effect of COVID-19 vaccines. Healthcare providers should be aware of this potential adverse event, and promptly recognize and manage it. However, the benefits of vaccination in reducing the morbidity and mortality associated with COVID-19 far outweigh the risks of this rare adverse event.
More Related Videos
14:18Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
09:29Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
Related Concept Videos
Acute Kidney Injury III: Clinical Manifestations
Allergic Drug Reactions
Myocarditis III: Medical Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Pyelonephritis I: Introduction
Endocarditis II: Clinical Features of Infective Endocarditis